Crizanlizumab Pregnancy Outcomes Intensive Monitoring
NCT07554547 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 13
Last updated 2026-04-28
Summary
This was a non-interventional study to evaluate pre-specified pregnancy and infant outcomes in women treated with crizanlizumab during pregnancy or within 105 days before the last menstrual period (LMP).
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceuticals · Novartis Pharmaceuticals
Eligibility
- Min Age
- 16 Years
- Max Age
- 100 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-11-15
- Primary Completion
- 2025-06-30
- Completion
- 2025-06-30
Countries
- Switzerland
Study Locations
More Related Trials
-
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
NCT04657822 ·Status: RECRUITING ·Phase: PHASE4
-
Crizanlizumab Improves Tissue Oxygen Supply Demand Matching in Patients With Sickle Cell Anemia
NCT05469828 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
NCT06975865 ·Status: RECRUITING ·Phase: PHASE3
-
SCRIPT: Sickle Cell Risk in Pregnancy Tool
NCT06529042 ·Status: ENROLLING_BY_INVITATION
-
An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients
NCT04662931 ·Status: COMPLETED ·Phase: PHASE4
-
Risk-based Therapy for Sickle Cell Anemia: A Feasibility Study
NCT02090296 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease
NCT03132324 ·Status: TERMINATED ·Phase: PHASE1
-
Decitabine for High-Risk Sickle Cell Disease
NCT01375608 ·Status: COMPLETED ·Phase: PHASE2
-
Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease
NCT06979492 ·Status: RECRUITING ·Phase: PHASE4
-
Future of Spermatogenesis in Men With Sickle Cell Disease Medically Treated
NCT01609192 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease
NCT05348915 ·Status: TERMINATED ·Phase: PHASE3
-
Clinical Study of BRL-101 in the Treatment of Sickle Cell Disease
NCT06287099 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD)
NCT03285178 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)
NCT03401112 ·Status: COMPLETED ·Phase: PHASE2
-
Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease
NCT02433158 ·Status: TERMINATED ·Phase: PHASE3
-
Efficacy Safety Study of Gene Therapy for Sickle Cell DiseaseSCD Using Autologous CD34+ Cells Transduced ex Vivo, Carrying a Corrected Globin Gene and a Silencing RNA.
NCT07432867 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Hydroxyurea Exposure Limiting Pregnancy and Follow-Up Lactation
NCT04093986 ·Status: RECRUITING
-
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
NCT01895361 ·Status: COMPLETED ·Phase: PHASE2
-
An Assessment of Prasugrel on Healthy Adults and Sickle Cell Adults
NCT01178099 ·Status: COMPLETED ·Phase: PHASE1
-
Effects of the Contraceptive Implant in Women With Sickle Cell Disease
NCT05730205 ·Status: RECRUITING ·Phase: PHASE4
-
A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
NCT06198712 ·Status: RECRUITING ·Phase: PHASE2
-
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
NCT06546670 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of IMR-687 in Subjects With Sickle Cell Disease
NCT04474314 ·Status: TERMINATED ·Phase: PHASE2
-
A Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (GRASP, BMT CTN 2001)
NCT05353647 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease
NCT01000155 ·Status: TERMINATED ·Phase: PHASE2